Genentech

( DNA) gained and

Eyetech

( EYET) fell Tuesday after the release of data showing the Lucentis treatment for macular degeneration prevented eyesight deterioration in 95% of patients taking it in a trial. Genentech, which developed the drug with

Novartis

(NVS) - Get Report

was adding $2.80, or 3.7%, to $79.40. Eyetech, which received FDA clearance for a similar produce in December, was down $9.56, or 40%, to $14.41.

Hughes Supply

( HUG) posted a profit of $34 million, or 51 cents a share, for the first quarter ended April 30, up from $29.8 million, or 48 cents a share, a year ago. Revenue for the quarter was $1.24 billion. The company matched analysts forecast of 51 cents a share on revenue of $1.24 billion, according to Thomson First Call. The stock was down 5 cents, or 0.18%, to $27.30 in after-hours trading.

Dycom Industries

(DY) - Get Report

said it earned $13.7 million, or 28 cents a share, for the third quarter ended April 30, compared with $11.2 million, or 23 cents a share, a year ago. Revenue for the quarter was $247.7 million. Analysts expected earnings of 25 cents a share on revenue of $243.4 million. For the fourth quarter, the company expects to earn 33 cents to 38 cents a share on revenue $250 million to $270 million, compared with Wall Street's forecast of 39 cents a share on revenue of $284.8 million. The stock was down $3.69, or 14.61%, to $21.57 in after-hours trading.

Israeli manufacturer

Eltek

(ELTK) - Get Report

said it earned $192,000, or 4 cents a share, for the first quarter ended March 31, compared with a loss of $587,000, or 8 cents a share a year ago. Revenue for the quarter was $7.9 million. The company also said it expects a decrease in revenues for the second quarter on a sequential basis, due to a short term flattening in the demand of production capacity. The stock was recently down 59 cents, or 20%, to $2.34.

JDS Uniphase

(JDSU)

announced it will buy privately held Acterna for $760 million. The purchase price will be divided between $450 million in cash and $310 million in stock. The deal is expected to close in the third quarter ending Sept. 30. JDS was upgraded to hold from sell at Smith Barney Tuesday and the stock was recently up 11 cents, or 7%, to $1.66.